Evidence map›Paper›PMID 36355989›Full record

ArticleToxins2022

A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.

Ryuji Kaji, Ai Miyashiro, Nori Sato, Taiki Furumoto, Toshiaki Takeuchi, Ryosuke Miyamoto, Tomoko Kohda, Yuishin Izumi, Shunji Kozaki

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ryuji KajiDepartment of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.ORCID 0000-0001-6207-1080
Ai MiyashiroDepartment of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.
Nori SatoDepartment of Rehabilitation Medicine, Tokushima University Hospital, Tokushima 770-8503, Japan.ORCID 0000-0003-1030-3673
Taiki FurumotoDepartment of Rehabilitation Medicine, Tokushima University Hospital, Tokushima 770-8503, Japan.
Toshiaki TakeuchiDepartment of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.
Ryosuke MiyamotoDepartment of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.
Tomoko KohdaLaboratory of Epidemiology, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka 598-8531, Japan.
Yuishin IzumiDepartment of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.
Shunji KozakiLaboratory of Epidemiology, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka 598-8531, Japan.
Tokushima University · JPNational Hospital Organization · JPOsaka Metropolitan University · JPTokushima University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

All the currently used type A botulinum neurotoxins for clinical uses are of subtype A1. We compared the efficacy and safety for the first time head-to-head between a novel botulinum toxin A2NTX prepared from subtype A2 and onabotulinumtoxinA (BOTOX) derived from A1 for post-stroke spasticity. We assessed the modified Ashworth scale (MAS) of the ankle joint, the mobility scores of Functional Independence Measure (FIM), and the grip power of the unaffected hand before and after injecting 300 units of BOTOX or A2NTX into calf muscles. The procedure was done in a blinded manner for the patient, the injecting physician, and the examiner. Stroke patients with chronic spastic hemiparesis (15 for A2NTX and 16 for BOTOX) were enrolled, and 11 for A2NTX and 13 for BOTOX (MAS of ankle; > or = 2) were entered for the MAS study. Area-under-curves of changes in MAS (primary outcome) were greater for A2NTX by day 30 (

Indexed as

Botulinum Toxins, Type ANeuromuscular AgentsStrokeHand StrengthHumansLower ExtremityMuscle SpasticityNeurotoxinsPilot ProjectsTreatment OutcomeBotulinum Toxins, Type ANeuromuscular AgentsNeurotoxinsA2NTXbotulinum neurotoxinclinical efficacyFunctional Independence Measurehand griponabotulinumtoxinAsafetyspasticity: modified Ashworth scalespreadsubtype A2

Identifiers

PMID36355989
PMCPMC9697926
OpenAlexW4307623851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.